Investor Presentaiton

H1 reported growth was up 14%, with ~6%-points impact from the Atos Medical acquisition and limited contribution from currencies H1 2022/23 Revenue development (DKKm) 1,495m DKK 633 57 12,166 804 10,671 Reported Organic growth revenue H1 21/22 (constant currencies) Acquired growth Currency effect Reported revenue H1 22/23 Growth 7.5% 5.9% 0.5% 14.0% • H1 2022/23 highlights Organic growth was 8% or DKK 804 million, driven by: • • • • Solid growth in Chronic Care across regions, ex. China China detracted from growth in Ostomy Care, as expected, negatively impacted by COVID-19 Continence Care growth was driven by solid performance of the Intermittent Catheters portfolio, partly offset by Collecting Devices which detracted from growth due to backorders Solid performance in Voice & Respiratory Care, with contributions from both Laryngectomy and Tracheostomy Wound Care performance driven by good momentum in Europe, partly offset by negative impact from backorders Strong momentum in Interventional Urology with broad- based growth, led by the US Men's Health business Acquired revenue contributed 6%-points to reported growth or DKK 633 million, reflecting 4 months impact from Atos Medical Foreign exchange rates had limited impact on reported growth (positive impact of around 50 bps), mainly related to appreciation of the USD against the DKK 6 Coloplast

View entire presentation